Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius ... Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok(R), an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. 詳細を表示
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire CRANFORD, N.J., Sept. 5, 2024 CEO Leonard Mazur to present on Tuesday, September...
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -23.5294117647 | 0.51 | 0.54 | 0.39 | 988492 | 0.46533559 | CS |
4 | -0.14 | -26.4150943396 | 0.53 | 0.61 | 0.39 | 961960 | 0.5172821 | CS |
12 | -0.342 | -46.7213114754 | 0.732 | 1.05 | 0.39 | 1649844 | 0.74851348 | CS |
26 | -0.595 | -60.4060913706 | 0.985 | 1.05 | 0.39 | 1841096 | 0.7088468 | CS |
52 | -0.28 | -41.7910447761 | 0.67 | 1.07 | 0.39 | 1248005 | 0.72405466 | CS |
156 | -1.65 | -80.8823529412 | 2.04 | 2.2499 | 0.39 | 1258889 | 1.13052306 | CS |
260 | -0.29 | -42.6470588235 | 0.68 | 4.56 | 0.39 | 2407960 | 1.74764015 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約